Clearmind Medicine Inc. has announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD). This announcement was made on December 16, 2025, and marks a significant step in the company’s mission to address major health issues with innovative therapies.
The second cohort consists of six patients, who were quickly recruited from three prominent clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. This rapid enrollment follows the successful completion of the first cohort, which yielded promising safety and efficacy data, including a favorable safety profile and initial indications of reduced cravings and withdrawal symptoms among participants.
The swift recruitment of participants reflects the dedication of the collaborating clinical centers to advance effective treatments for AUD, a condition that affects millions globally and often lacks adequate treatment options. “We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment,” stated Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.
The multinational Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients suffering from moderate to severe AUD. Dosing for the second cohort is expected to commence shortly, with topline results anticipated in the coming months.
Innovative Approach to Alcohol Use Disorder
Clearmind Medicine is a clinical-stage biotechnology firm focused on developing novel neuroplastogen-derived therapeutics. The company’s primary objective is to create psychedelic-based treatments for various health problems, including AUD. Clearmind’s intellectual property currently includes nineteen patent families, encompassing 31 granted patents, with plans to pursue additional patents as warranted.
The results from the first cohort have provided a robust foundation for the continued development of CMND-100. The potential of this drug to offer improved safety and efficacy is seen as a breakthrough in addiction treatment, addressing underlying causes rather than merely alleviating symptoms.
The company’s commitment to innovation and operational excellence is evident in its collaborative efforts with esteemed clinical sites. These partnerships aim to generate valuable data that could significantly advance the treatment landscape for AUD.
As Clearmind Medicine moves forward, investors and stakeholders will be closely monitoring the outcomes of the second cohort. The company’s shares are traded on Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under “CWY0.”
In conclusion, the successful completion of enrollment for the second cohort represents a promising development in the quest for effective treatments for Alcohol Use Disorder, showcasing Clearmind Medicine’s potential to deliver transformative therapies to those in need.
